

Mariella Spalato Ceruso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6023893/publications.pdf>

Version: 2024-02-01

20
papers

266
citations

840776

11
h-index

940533

16
g-index

20
all docs

20
docs citations

20
times ranked

480
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug-induced hepatotoxicity in cancer patients - implication for treatment. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1219-1238.	2.4	52
2	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. <i>PLoS ONE</i> , 2014, 9, e105268.	2.5	33
3	New frontiers in the medical management of gastrointestinal stromal tumours. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984194.	3.2	33
4	Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879462.	3.2	27
5	Recent Advances in Desmoid Tumor Therapy. <i>Cancers</i> , 2020, 12, 2135.	3.7	18
6	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. <i>Clinical Cancer Research</i> , 2022, 28, 1672-1679.	7.0	18
7	Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. <i>Oncotarget</i> , 2016, 7, 69412-69419.	1.8	17
8	Olaratumab: PDGFR- α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 118, 1-6.	4.4	16
9	Use of Cardioprotective Dexrazoxane Is Associated with Increased Myelotoxicity in Anthracycline-Treated Soft-Tissue Sarcoma Patients. <i>Chemotherapy</i> , 2019, 64, 105-109.	1.6	14
10	Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 971-976.	2.4	12
11	Familial adenomatous polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. <i>ESMO Open</i> , 2020, 5, e000604.	4.5	11
12	Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin. <i>Oncology</i> , 2018, 95, 1-7.	1.9	7
13	Implementing a Machine Learning Strategy to Predict Pathologic Response in Patients With Soft Tissue Sarcomas Treated With Neoadjuvant Chemotherapy. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 958-972.	2.1	3
14	Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study. <i>Scientific Reports</i> , 2015, 5, 12077.	3.3	2
15	Unexpected benefit from an "old" metronomic chemotherapy regimen in advanced chordoma. <i>BMJ Case Reports</i> , 2019, 12, e228728.	0.5	2
16	Second-line treatment in exon 11-mutated GIST patients: Imatinib dose escalation or sunitinib? Retrospective analysis of a multi-institutional experience.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10515-10515.	1.6	1
17	Trabectedin-related liver toxicity in soft tissue sarcoma patients: Always a good reason to discontinue the treatment?. <i>Journal of Clinical Oncology</i> , 2014, 32, 10572-10572.	1.6	0
18	Rechallenge in advanced GIST progressing to imatinib, sunitinib and regorafenib: An Italian survey.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11038-11038.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Advanced epithelioid haemangioendotelioma: Fever, pain, and pleural effusion predict a worse outcome.. Journal of Clinical Oncology, 2019, 37, e22540-e22540.	1.6	0
20	Use of cardioprotective dexrazoxane and myelotoxicity in anthracycline-treated soft tissue sarcoma patients.. Journal of Clinical Oncology, 2019, 37, 11053-11053.	1.6	0